Interferon-gamma (IFN-␥) is an important cytokine that regulates cellular immune responses
Introduction
Interferon-gamma (IFN-␥) is a cytokine essential in the development and propagation of T helper 1 (Th1) type immune responses. The regulation of IFN-␥ gene transcription is complex and several transcription factors have been found to interact with the proximal promoter constitutively 1 or by induction. 2 The consequence of aberrant expression of IFN-␥ has been determined in transgenic mouse models whereby over-expression of IFN-␥ resulted in B, T, and hematopietic cell deficiencies, 3 while disruption of the IFN-␥ gene lead to susceptibility to intracellular pathogens. 4 Thus, the control of IFN-␥ expression is tightly regulated.
The human IFN-␥ gene on chromosome 12q24.1, spans approximately 5.4 kb and contains four exons that encode a protein of 146 amino acids. Like other cytokines, the IFN-␥ coding region is invariant with no reported polymorphisms. 5 However, promoter single nucleotide polymorphisms (SNPs) in the IL-4, 6 and TNF-␣ RANTES, 13 and SDF-1 14 with HIV-1 infection and AIDS progression rates, IL-1B with gastric cancer, 15 and TNF-␣ with severe malaria. 8 We recently conducted a polymorphism discovery screen of the entire IFN-␥ gene including the proximal promoter and a portion of the 3Ј untranslated region (UTR) in an attempt to better understand inter-individual variation in IFN-␥ expression. 16 We reported several novel SNPs in introns and the 3ЈUTR but noted that the proximal promoter is invariant in predominately Caucasian populations. In a separate study, a rare SNP, −333CϾT, was found in the IFN-␥ promoter but its function is unknown. 17 Since different selective forces may be operative in other ethnic or racial groups we expanded our screening to include African Americans.
Results

Polymorphism frequency and distribution
Using a polymorphism discovery panel that includes 72 African Americans, two new SNPs were identified: A G to T transition at position −179 in the promoter and a C to T transition at position +445 in the first intron. The +445C/T genotype was detected in one African American (n = 72) and was absent among in European Americans (n = 72). Because this variant was rare, it was not genotyped on the larger group of African-and European Americans ( Table 1 ). The −179T variant was infrequent in African Americans and not polymorphic European Americans (f = 0.001). We also genotyped a group of 59 HIV-1 uninfected normal African American blood donors: one −179T/C heterozygote was detected (Table 1) . There were no significant differences in allele frequencies between HIV-1 seronegatives at risk for HIV-1 exposure and HIV-1 infected African Americans (P Ͼ 0.5, twotailed Fisher exact test (FET)) or between all African Americans enrolled in the HIV-1 cohorts and HIV-1 uninfected NIH blood bank donors (P Ͼ 0.5, FET).
Allele-specific DNA-binding proteins
By computer analysis the G to T transition at −179 creates a putative activator protein 1 (AP-1) binding element. 18 No differences were predicted or observed in DNAbinding assays for the +445 site. At the −179 site however, electrophoretic mobility shift assay (EMSA) revealed the binding of a unique, constitutively bound complex 179T but not to the common −179G probe ( Figure 1 ). Since the T-bearing variant allele creates a potential AP-1 binding site, we performed cold competition with a consensus AP-1 oligonucleotide ( Figure 1 ) and supershift analysis with a pan anti-jun antibody (data not shown) to detect AP-1 binding. The results indicate that AP-1 family members are not in the −179T-specific complex (complex 1).
Transcriptional activation by TNF-␣
To investigate the role of this SNP in the regulation of IFN-␥ promoter activity we preformed site-directed mutagenesis on an IFN-␥ promoter reporter construct, −204 to +38/Luc. 
Discussion
We report here the first functional variant in the IFN-␥ promoter. Although we previously screened the promoter region of the IFN-␥ gene in a predominately Caucasian population for variants, no polymorphic sites were discovered. 16 By expanding our search to include a large A recent paper described a low-frequency TNF promoter allele that is found in approximately 5% of native Africans. 8 The authors establish that this TNF promoter SNP creates a functional OCT-1 binding site, alters transcriptional activation, and is associated with increased susceptibility to cerebral malaria. In our study, the −179T SNP creates a DNA-binding site similar in sequence to an AP-1 site (Table 2 ) and by EMSA we confirmed the binding of a −179T-specific DNA-protein complex (Figure 1) .
Interestingly, in cold competition experiments, the −179T AP-1-like motif (TGACCCA) has been shown to be incapable of competing for AP-1 binding to a consensus TGACTCA site (Table 2 ) despite similarities in sequence homology. 21 As yet we have not identified the protein(s) in complex 1, however, these factor(s) are exclusively in the nuclear fraction as cytoplasmic protein extracts fail to generate binding of complex 1 to −179T-containing probes (data not shown). In addition, the nuclear proteins in complex 1 are not inducible in human T cells and constituitively interact with −179T probes of various lengths. Thus, these data indicate that the −179T SNP creates a binding site for a nuclear transcription factor(s) that requires TNF-␣-induced posttranslational modification(s) to confer transcriptional activation to the IFN-␥ promoter. Stimulation-induced phosphorylation of pre-bound transcription factors has been reported for a variety of DNAbinding proteins including AP-1, 22 and is thought to be an alternative mechanism of transcriptional regulation. 23 The functional consequences of this polymorphism have yet to be determined, but may disproportionately affect the immune response to intracellular pathogens. In regards to endogenous IFN-␥ expression, the influence of this allele has not been resolved due to difficulties in identifying individuals homozygous for the variant allele. Nevertheless, as gut disorders (eg, inflammatory bowl disease, and Crohn's disease) are generally more severe in African Americans, it will be of great interest to determine if this SNP has a higher frequency in these diseases.
Genes and Immunity
Materials and methods
Study design
Participants were 1451 European Americans and 1115 African Americans enrolled in the following HIV-1 natural history cohort studies: ALIVE (AIDS Link to the Intravenous Experience); 24 MACS (Multicenter AIDS Cohort study, homosexual), 25 HGDS (hemophilia Growth and Development Study, hemophiliacs), 26 MHCS (Multicenter hemophiliac Cohort Study, hemophiliac) 27 and SFCC (San Francisco City Clinic Study, homosexual). 27, 28 In addition, 59 normal African American normal volunteer donors from the NIH blood bank were genotyped. DNA samples used in the polymorphism discovery panel represented 72 European-and 72 African Americans selected from the cohort population (24 each rapid progressors to AIDS, high risk uninfected, and long-term nonprogressors). All participants provided blood samples after obtaining informed consent.
Polymorphism discovery
The polymerase chain reaction single-strand conformation polymorphism assay (PCR-SSCP) was performed to screen for polymorphisms in a DNA panel discovery. A series of overlapping PCR primers was employed to cover four exons, exon-intron junctions, and the promoter region to position −536 (numbering relative to transcriptional start site 14 ) . PCR primer sequences used are available upon request. The −179 SNP was previously registered in Genbank with accession number AF114159.
Genotyping of −179 G/T polymorphism
The SNP −179 G/T alleles were determined by a PCRrestriction fragment length polymorphism (RFLP) assay using the PCR primers: 5Ј-atcaatgtgctttgtgaatgaa-3Ј and 5Ј-ccgagagaattaagccaaaga-3Ј. PCR was performed in a 20- 
Cell culture
Tissue culture media contained RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutimine, 1 × essential amino acids, sodium pyruvate, 10 mM 2-mercaptoethanol, 100 U/ml penicillin, and 100 g/ml streptomycin. Stable Jurkat T cells transfected with the p80 subunit of the TNF-␣ receptor (p80 Jurkat) were provided by Michael J Lenardo.
20
Nuclear extraction Nuclear extracts were prepared from PHA-blasted fresh human peripheral blood T cells as described previously. . EMSA experiments were performed as previously described. 16 In cold oligonucleotide competition experiments, 100-fold excess of unlabeled, probe was added 30 min prior to adding the radiolabeled oligonucleotide probe. Sequences for previously determined sites include: AP-1: 5Ј-GATCCGTGACTCAGCGCG-3Ј 30 SP-1: 5Ј-GGGAGGCGTGGCCTGGGCGGACTGGGGAGT GGCGA-3Ј. 31 
IFN-␥ promoter constructs
The −204 to +38 human IFN-␥ promoter-luciferase construct was described previously. 19 Using the −204 construct as a template, site-directed mutagenesis was used to create the −204(179T) variant (QuickChange; Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. Both constructs were confirmed by sequencing.
Transient transfections
Exponentially growing BFS (murine T-lymphoma cell line) or p80 Jurkat cells were plated at a density of 1×10 4 cells/cm 3 on a 12-well plate and allowed to grow at 37°C for 24 h prior transfection. Cells were transfected using Fugene-6 reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions with 1 g of −204(−179G)/Luc. or −204(−179T)/Luc. vector together with 0.2 g of pRL-Tk vector (Promega, Madison, WI, USA). The ratio of IFN-␥ promoter construct to pRL-Tk was 80:1 and thus, the readout is promoter luciferase activity/pRL-Tk luciferase activity. Twenty-four hours after transfection, cells were treated with 10 ng/ml recombinant human TNF-␣. As a positive control, we determined that the −204 (−179G)/Luc and the −204(−179T)/Luc constructs were equally inducible with PMA/ionomycin stimulation. Each experiment was repeated three times and was confirmed with two separate DNA plasmid preparations. Luciferase activity was determined by Dual-luciferase assay (Promega) according to the manufacturer's instructions.
Note in proof
While this manuscript was in press, another group reported an IFN-gamma promoter SNP similar to ours (Chevillard C, Henri S, Stefani F, Parzy D, Dessein A. Two new polymorphisms in the human interferon gamma (IFN-gamma) promoter. Eur J Immunogenet 2002; 29: 53-56). We have determined that our promoter SNP, IFN-␥-179G/T, is identical to the −183 SNP reported in their paper. For clarification, our nomenclature system was reported previously in reference 16.
